Abstract
Minimal (measurable) residual disease (MRD) in acute leukemia denotes the presence of leukemic cells detected by multiparameter flow cytometry or various molecular techniques in patients achieving hematological remission. The MRD become an independent, post-diagnosis, prognostic indicator important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis in acute myeloid leukemia (AML). However, several issues remain with regard to the ideal time point to measure MRD, the clinically significant threshold, the sample (peripheral blood or bone marrow) should be used, and the standardize tests, so that results from different laboratories become comparable. This review gives an overview of the currently available evidence regarding technical issues, prognostic impact, and MRD-directed treatment for AML.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
